Coeptis Therapeutics Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| COEPTIS THERAPEUTICS HOLDINGS, INC. | ||
| Date: March 19, 2026 | By: | /s/ David Mehalick |
|---|---|---|
| David Mehalick | ||
| Chief Executive Officer (Principal Executive Officer) | ||
| Date: March 19, 2026 | By: | /s/ Brian Cogley |
| Brian Cogley | ||
| Chief Financial Officer (Principal Financial and Accounting Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ David Mehalick | Chief Executive Officer | March 19, 2026 |
| David Mehalick | (Principal Executive Officer) and Director | |
| /s/ Brian Cogley | Chief Financial Officer | March 19, 2026 |
| Brian Cogley | (Principal Financial and Accounting Officer) and Director | |
| /s/ Daniel Yerace | Director | March 19, 2026 |
| Daniel Yerace | ||
| /s/ Christopher Calise | Director | March 19, 2026 |
| Christopher Calise | ||
| /s/ Christopher Cochran | Director | March 19, 2026 |
| Christopher Cochran | ||
| /s/ Philippe Deschamps | Director | March 19, 2026 |
| Philippe Deschamps | ||
| /s/ Tara DeSilva | Director | March 19, 2026 |
| Tara DeSilva | ||
| /s/ Gene Salkind | Director | March 19, 2026 |
| Gene Salkind | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Consolidated Financial Statements
Years Ended December 31, 2025 and 2024
| Pages | |
| Report of Independent Registered Public Accounting Firm PCAOB Firm ID 6920 | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-3 |
| Consolidated Statements of Operations for the years ended December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.